HIV viral suppression after enhanced adherence counselling in children on dolutegravir-based regimens in Malawi

HIV viral suppression after enhanced adherence counselling in children on dolutegravir-based regimens in Malawi

Background: Viral suppression (VS) rates in children on antiretroviral therapy (ART) are lower than in adults. We described the effect of enhanced adherence counselling (EAC) on VS among children with high HIV viral load accessing dolutegravir (DTG)-based ART in a programme setting in Malawi. Objec...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lucky Makonokaya, Maggie Khumbanyiwa, Louiser U. Kalitera, Rachel Chamanga, Shalom Dunga, Lilian Jiah, Elton Masina, Nilesh B. Bhatt, Thulani Maphosa
Format:	Article
Language:	English
Published:	AOSIS 2025-05-01
Series:	Southern African Journal of HIV Medicine
Subjects:	enhanced adherence counselling children living with hiv viral suppression hiv dolutegravir malawi
Online Access:	https://sajhivmed.org.za/index.php/hivmed/article/view/1692
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique
by: Nalia Ismael, et al.
Published: (2025-01-01)

Hospitalization outcomes in people living with HIV on Dolutegravir-based regimen in Mwanza, Tanzania: a comparative cohort
by: Godfrey A. Kisigo, et al.
Published: (2025-02-01)

Longer-term virologic outcomes on tenofovir-lamivudine-dolutegravir in second-line ART
by: Jennifer K. van Heerden, et al.
Published: (2025-04-01)

Invasive salmonellosis in Malawi
by: Melita A. Gordon, et al.
Published: (2008-12-01)

Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database
by: Juan Su, et al.
Published: (2025-07-01)

Hypertension among people living with HIV receiving dolutegravir-based antiretroviral therapy in ethiopia: a cross-sectional study
by: Mohammed Jemal, et al.
Published: (2025-07-01)

Effectiveness of dolutegravir-based treatment among HIV/AIDS patients in Nkembo Outpatient Treatment Center, Gabon
by: Christian Mangala, et al.
Published: (2025-05-01)

Persistent sex disparities in access to dolutegravir‐based antiretroviral therapy in Latin America and the Caribbean: results from a retrospective observational study using data from 2017 to 2022
by: Fernanda F. Fonseca, et al.
Published: (2025-07-01)

Patterns of peri-gestational weight change among women living with HIV in Nigeria receiving dolutegravir compared to alternative antiretroviral regimens: a retrospective cohort study
by: Ammar Al Naimi, et al.
Published: (2025-03-01)

Quality-of-life changes six months after the programmatic switch from nevirapine to dolutegravir-based ART in stable PLWH: a prospective cohort study in Indonesia
by: Meivina Ramadhani Pane, et al.
Published: (2025-08-01)

Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART
by: Kirusha Naidoo, et al.
Published: (2025-04-01)

Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
by: Eric S. Daar, et al.
Published: (2025-04-01)

The association between dolutegravir based first-line antiretroviral regimens and dyslipidemia among adults living with HIV on follow-up at health facilities in Hawassa city administration, Sidama region: a cross-sectional study
by: Agete Tadewos Hirigo, et al.
Published: (2025-09-01)

Safe Switch to an Oral Two‐Drug Regimen Based on Dolutegravir in People With Vertically Acquired HIV‐1: An Observational Multicenter Study
by: Giulia Meraviglia, et al.
Published: (2025-07-01)

HIV drug resistance in children and adolescents on NNRTI-based antiretroviral therapy and subsequent virologic response to dolutegravir-based regimens in Ghana
by: Adwoa K.A Afrane, et al.
Published: (2025-07-01)

First Reported Case of Integrase Strand Transfer Inhibitor Resistance in Suriname: Unusual Drug Resistance Mutations Following Exposure to Dolutegravir
by: Rachel C. Sno, et al.
Published: (2025-02-01)

Spectrum and Correlates of Dyslipidemia in People Living with HIV on Dolutegravir-Based Regimen Attending Kabutare Hospital, Southern Rwanda: A Cross-Sectional Study
by: Nsengumuremyi H, et al.
Published: (2025-07-01)

Cervical cancer screening uptake among women living with HIV in the era of universal test and treat policy in Malawi: results from the 2020–2021 Malawi population-based HIV impact assessment
by: Chrispin Mandiwa, et al.
Published: (2025-07-01)

Impact of switching to a dolutegravir‐based regimen on body weight changes: insights from West African adult HIV cohorts
by: Thierry Tiendrebeogo, et al.
Published: (2024-12-01)

Impaired creatinine-based estimated glomerular filtration rate in Thai individuals switching to dolutegravir: illustrating the role of cystatin C testing to aid clinical decision making
by: Carlo Sacdalan, et al.
Published: (2025-02-01)

The impact of adherence counseling incorporating a point of care urine tenofovir assay on virologic suppression among individuals failing tenofovir-lamivudine-dolutegravir: A pre-post intervention study
by: Leonard Bikinesi, et al.
Published: (2025-02-01)

Impact of Dolutegravir-based regimens on patient satisfaction and quality of life among people living with HIV: A systematic review and meta-analysis protocol
by: Mustapha Muhammed Abubakar, et al.
Published: (2025-08-01)

"Life mapping" exploring the lived experience of COVID-19 on access to HIV treatment and care in Malawi [version 2; peer review: 2 approved]
by: Ruby T. Zolowere, et al.
Published: (2024-09-01)

Gut microbiota differences linked to weight gain and ART in people living with HIV are enterotype specific and minor compared to the large differences linked to sexual behavior
by: Jan Kehrmann, et al.
Published: (2025-05-01)

Low-level viremia in people with HIV in Ethiopia is associated with subsequent lack of viral suppression and attrition from care
by: Ilili Jemal Abdulahi, et al.
Published: (2025-12-01)

Differential associations of anti-cytomegalovirus antibodies and soluble CD14 levels with immunosenescence in people living with HIV on long term antiretroviral therapy
by: Ashwini Vinod Shete, et al.
Published: (2024-12-01)

Hyperglycaemia and Its Risk Factors Among Adults Living With HIV on Follow‐Up at the Hawassa City Administration, Southern Ethiopia: A Cross‐Sectional Study
by: Agete Tadewos Hirigo, et al.
Published: (2025-05-01)

Impact of an optimized care model for advanced HIV disease: a non-randomized cluster study in Malawi
by: Thulani Maphosa, et al.
Published: (2025-08-01)

Clinical Officers in Malawi
by: R. Thetard, et al.
Published: (2004-03-01)

Effect of differentiated service delivery models for HIV treatment on healthcare providers’ job satisfaction and workloads in sub-Saharan Africa: a mixed methods study from Malawi, Zambia, and South Africa
by: Vinolia Ntjikelane, et al.
Published: (2025-05-01)

Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation integrase inhibitors
by: Daniele Armenia, et al.
Published: (2025-06-01)

Dolutegravir Derivatives Alleviate LPS-Induced Microglial Inflammation by Suppressing STAT1/3 Nuclear Translocation
by: Wang L, et al.
Published: (2025-05-01)

Study design and procedures for a hybrid effectiveness-implementation incomplete stepped-wedge cluster-randomized trial to evaluate a differentiated point-of-care HIV diagnosis and management model for the prevention of vertical transmission of HIV in Malawi: The PAC-Man trial protocol
by: Michael E. Herce, et al.
Published: (2025-07-01)

Sex differences in discontinuations due to side effects of second-generation integrase strand transfer inhibitors: a systematic review and meta-analysisResearch in context
by: Zhou Fang, et al.
Published: (2025-06-01)

Examining teen club attendance and viral load suppression among adolescents under differentiated HIV care in Malawi: a sub-optimal scenario
by: Rachel Chamanga, et al.
Published: (2024-12-01)

Incidence and determinants of excessive weight gain in people living with HIV initiating tenofovir, lamivudine, and dolutegravir-based therapy: a multicenter retrospective study in northwest Ethiopia
by: Gashaw Sisay Chanie, et al.
Published: (2025-04-01)

Characteristics of individuals who received post‐exposure prophylaxis and HIV seroconversion in Malawi: an analysis of national routine HIV testing data
by: Hannock Tweya, et al.
Published: (2025-06-01)

Slow virologic control but strong immune and metabolic recovery with dolutegravir-anchored therapy in an HIV cohort in Ghana
by: Mark Appeaning, et al.
Published: (2025-07-01)

Effectiveness of dolutegravir in moderate severity COVID-19 patients: A single-center, randomized, double-blind, placebo-controlled trial
by: Hamideh Abbaspour Kasgari, et al.
Published: (2024-06-01)

Parkinsonism amongst white missionary workers in Malawi: 1889- 1989
by: F.P. Retief, et al.
Published: (2003-10-01)